Autolus: Investment Case Further Entrenched With Latest Interim FELIX Data

Terry Chrisomalis
Investing Group Leader

Summary

  • Primary endpoint met with interim analysis released from phase 1b/2 FELIX study using obe-cel for the treatment of patients with relapsed/refractory Acute Lymphoblastic Leukemia; 70% Overall Remission Rate achieved.
  • Recently released positive interim analysis results with obe-cel for relapsed/refractory Acute Lymphoblastic Leukemia to be presented at medical conference mid-2023; Final results to be released by end of 2023.
  • Biologics Licensing Application to the FDA of obe-cel for the treatment of patients with relapsed/refractory Acute Lymphoblastic Leukemia to be filed before end of 2023.
  • Autolus has been able to establish three partnerships based on its two CAR technologies it has, which are with Moderna, Bristol Myers Squibb and Cabaletta Bio.
  • Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More »
Woman scientist hand write note information in medical lab look at science microscope medical test, research biology chemistry. Asian Females technician laboratory analyzing blood test pharmaceutical

howtogoto/iStock via Getty Images

Autolus Therapeutics (NASDAQ:AUTL) is a great speculative biotech play to look into. The reason why I state that is because it has gone on and accomplished what I talked about in the prior article I wrote , which is

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.

This article was written by

Terry Chrisomalis
13.46K Followers

Terry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare.

He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About AUTL Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on AUTL

Related Stocks

SymbolLast Price% Chg
AUTL
--
Compare

Trending Analysis

Trending News